Shanghai INT Medical Instruments Co., Ltd. (INT Medical) announced three board approvals dated 17 November 2026:
1. Compressed validity for A-share listing resolutions The Board reduced both the validity of the Issuance Resolution and the authorisation period for handling the ChiNext Market listing from 24 months to 12 months, counted from the forthcoming shareholders’ meeting approval. All other terms remain unchanged.
2. Planned domestic auditor replacement for FY 2026 To streamline work for the planned A-share offering, the Board will seek shareholder approval to replace KPMG Huazhen LLP with BDO China Shu Lun Pan Certified Public Accountants LLP as domestic auditor for 2026. • Expected audit fee: RMB0.50 million, up from RMB0.40 million for KPMG Huazhen in 2025, reflecting anticipated business expansion and a wider consolidation scope. • KPMG will continue as international auditor for Hong Kong Financial Reporting Standards. • Both the Board and KPMG Huazhen report no disagreements or unresolved issues related to the change.
3. Proposed RMB1.43 billion guarantees for six subsidiaries To support operating and financing needs, INT Medical plans to extend joint-and-several guarantees of up to RMB1.43 billion to six consolidated subsidiaries: • Shandong INT Medical Instruments – RMB0.70 billion • Hangzhou INT Medical Technology – RMB0.40 billion • Xiamen INT Medical Technology – RMB0.15 billion • Shanghai INT Purun Medical Instruments – RMB0.10 billion • Shanghai INT Biotechnology – RMB0.05 billion • Shanghai Qimu Medical Instruments – RMB0.03 billion
The guarantees do not constitute notifiable or connected transactions under Hong Kong Listing Rules.
A circular containing details of the auditor change and guarantees, plus the notice of the general meeting, will be dispatched to shareholders in due course.
Comments